April 17, 2012
Today, the U.S. Supreme Court rendered its decision in Caraco Pharmaceutical Laboratories, LTD. v. Novo Nordisk A/S. The Court held that a generic pharmaceutical manufacturer may bring a counterclaim to force correction of a brand manufacturer's "use code" that inaccurately describes the patent as covering a particular method of using the drug in question.